CFTR biomarkers: Time for promotion to surrogate end-point?

European Respiratory Journal

Volumn 41, Issue 1, 2013, Pages 203-216

  De Boeck, K ^a   Kent, L ^b   Davies, J ^c   Derichs, N ^d   Amaral, M ^e,f   Rowe, S M ^g   Middleton, P ^h   De Jonge, H ⁱ   Bronsveld, I ^j   Wilschanski, M ^k   Melotti, P ^l   Danner Boucher, I ^m   Boerner, S ⁿ   Fajac, I ^o   Southern, K ^p   De Nooijer, R A ^j   Bot, A ^q   De Rijke, Y ⁱ   De Wachter, E ^r   Leal, T ^s   Vermeulen, F ^a   Hug, M J ^t   Rault, G ^u   Nguyen Khoa, T ^v   Barreto, C ^w   Proesmans, M ^a   Sermet Gaudelus, I ^v   more..

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF ULSTER   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF LISBON   (Portugal)

^f UNIVERSITY OF LISBON   (Portugal)

^g University of Alabama at Birmingham   (United States)

^h WESTMEAD HOSPITAL   (Australia)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^k HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^l UNIVERSITY HOSPITAL OF VERONA   (Italy)

^m CHU de Nantes   (France)

ⁿ UNIVERSITY OF COLOGNE   (Germany)

^o University of Liverpool ^*  (France)

^p UNIVERSITY OF LIVERPOOL   (United Kingdom)

^q SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^r UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^s UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^t UNIVERSITY OF FREIBURG   (Germany)

^u Centre de Perharidy   (France)

^v HÔPITAL NECKER ENFANTS MALADES   (France)

^w HOSPITAL DE SANTA MARIA   (Portugal)

more..

Author keywords

Clinical trials; Cystic fibrosis transmembrane conductance regulator; Intestinal current measurement; Nasal potential difference; Surrogate end point; Sweat test

Indexed keywords

BIOLOGICAL MARKER; CHLORIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;

BIOASSAY; CYSTIC FIBROSIS; FEASIBILITY STUDY; HUMAN; INTERMETHOD COMPARISON; NONHUMAN; NORMAL VALUE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN DETERMINATION; RELIABILITY; REVIEW; SWEAT TEST; VALIDATION PROCESS;

BIOLOGICAL MARKERS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; REPRODUCIBILITY OF RESULTS;

EID: 84872190665     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00057512     Document Type: Review

References (101)

1. De Gruttola VG, Clax P, DeMets DL, et al. Considerations in the evaluation of surrogate endpoints in clinical trials. Summary of a National Institutes of Health workshop. Control Clin Trials 2001; 22: 485-502.
2. Atkinson A, Colburn W, Gruttola VD, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
3. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl JMed 1994; 331: 637-642.
4. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340: 23-30.
5. Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010; 45: 1121-1134.
6. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Guidance for Industry: Patient-reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Health USDo, editor. Rockville, Food and Drug Administration, 2006.
7. Quittner A, Sawicki G, McMullen A, et al. Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample. Qual Life Res, 2011: 1-12.
8. Committee for Medicinal Products for Human Use. Guideline on the Clinical Development of Medicinal Products for the Treatment of Cystic Fibrosis. London, European Medicines Agency, 2009.
9. Corey M, Edwards L, Levison H, et al. Longitudinal analysis of pulmonary function decline in patientswith cystic fibrosis. J Pediatr 1997; 131: 809-814.
10. 1 in young adults with cystic fibrosis. Thorax 2006; 61: 155-157.
11. Konstan MW, Wagener JS, Yegin A, et al. Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint. J Cyst Fibros 2010; 9: 332-338.
12. Ramsey BW. Outcome measures for development of new therapies in cystic fibrosis: are we making progress and what are the next steps? Proc Am Thorac Soc 2007; 4: 367-369.
13. Mayer-Hamblett N, Ramsey BW, Kronmal RA. Advancing outcome measures for the new era of drug development in cystic fibrosis. Proc Am Thorac Soc 2007; 4: 370-377.
14. Rosenfeld M. An overview of endpoints for cystic fibrosis clinical trials: one size does not fit all. Proc Am Thorac Soc 2007; 4: 299-301.
15. Greenhalgh J, Long AF, Brettle AJ, et al. Reviewing and selecting outcome measures for use in routine practice. J Eval Clin Pract 1998; 4: 339-350.
16. Davies JC, Alton EW. Gene therapy for cystic fibrosis. Proc Am Thorac Soc 2010; 7: 408-414.
17. Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003; 349: 1433-1441.
18. Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008; 372: 719-727.
19. Sermet-Gaudelus I, Boeck KD, Casimir GJ, et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med 2010; 182: 1262-1272.
20. Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010; 363: 1991-2003.
21. Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012; 67: 12-18.
22. Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 1998; 132: 589-595.
23. De Boeck K, Wilschanski M, Castellani C, et al. Cystic fibrosis: terminology and diagnostic algorithms. Thorax 2006; 61: 627-635.
24. Farrell PM, Rosenstein BJ, White TB, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008; 153: S4-S14.
25. De Boeck K, Derichs N, Fajac I, et al. New clinical diagnostic procedures for cystic fibrosis in Europe. J Cyst Fibros 2011; 10: Suppl. 2, S53-S66.
26. Green A. Guidelines for the Performance of the Sweat Test for the Investigation of Cystic Fibrosis in the UK. Royal College of Paediatrics and Child Health, 2003. Available from www.acb.org.uk/docs/sweat.pdf
27. Quinton PM. Chloride impermeability in cystic fibrosis. Nature 1983; 301: 421-422.
28. Knowles MR, Paradiso AM, Boucher RC. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 1995; 6: 445-455.
29. Middleton PG, Caplen NJ, Gao X, et al. Nasal application of the cationic liposome DC-Chol:DOPE does not alter ion transport, lung function or bacterial growth. Eur Respir J 1994; 7: 442-445.
30. + transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation. J Clin Invest 1986; 78: 1245-1252.
31. + conductance in cystic fibrosis. Pflugers Arch 1995; 431: 1-9.
32. - channel function. Nature 1999; 402: 301-304.
33. Chen JH, Stoltz DA, Karp PH, et al. Loss of anion transport without increased sodium absorption characterizes newborn porcine cystic fibrosis airway epithelia. Cell 2010; 143: 911-923.
34. + conductance. Proc Natl Acad Sci USA 2011; 108: 10260-10265.
35. Veeze HJ, Halley DJ, Bijman J, et al. Determinants of mild clinical symptoms in cystic fibrosis patients. Residual chloride secretion measured in rectal biopsies in relation to the genotype. J Clin Invest 1994; 93: 461-466.
36. De Jonge HR, Ballmann M, Veeze H, et al. Ex vivo CF diagnosis by intestinal current measurements (ICM) in small aperture, circulating Ussing chambers. J Cyst Fibros 2004; 3: Suppl. 2, 159-163.
37. Derichs N, Sanz J, Von Kanel T, et al. Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data. Thorax 2010; 65: 594-599.
38. Vermeulen F, Proesmans M, Feyaerts N, et al. Nasal potential measurements on the nasal floor and under the inferior turbinate: does it matter? Pediatr Pulmonol 2011; 46: 145-152.
39. Jaron R, Yaakov Y, Rivlin J, et al. Nasal potential difference in non-classic cystic fibrosis-long term follow up. Pediatr Pulmonol 2008; 43: 545-549.
40. Yaakov Y, Kerem E, Yahav Y, et al. Reproducibility of nasal potential difference measurements in cystic fibrosis. Chest 2007; 132: 1219-1226.
41. Middleton PG, House HH. Measurement of airway ion transport assists the diagnosis of cystic fibrosis. Pediatr Pulmonol 2010; 45: 789-795.
42. Ahrens RC, Standaert TA, Launspach J, et al. Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis. Pediatr Pulmonol 2002; 33: 142-150.
43. Delmarco A, Pradal U, Cabrini G, et al. Nasal potential difference in cystic fibrosis patients presenting borderline sweat test. Eur Respir J 1997; 10: 1145-1149.
44. Hofmann T, Bohmer O, Huls G, et al. Conventional and modified nasal potential-difference measurement in cystic fibrosis. Am J Respir Crit Care Med 1997; 155: 1908-1913.
45. Alton EW, Currie D, Logan-Sinclair R, et al. Nasal potential difference: a clinical diagnostic test for cystic fibrosis. Eur Respir J 1990; 3: 922-926.
46. Sermet-Gaudelus I, Renouil M, Fajac A, et al. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. BMC Med 2007; 5: 5.
47. Clancy JP, Rowe SM, Bebok Z, et al. No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. Am J Respir Cell Mol Biol 2007; 37: 57-66.
48. Clancy JP, Bebok Z, Ruiz F, et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 2001; 163: 1683-1692.
49. Wilschanski M, Famini C, Blau H, et al. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med 2000; 161: 860-865.
50. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365: 1663-1672.
51. Aherns R. VX-770 in subjects 6 to 11 years with cystic fibrosis and the G551D-CFTR mutation. Pediatr Pulmonol 2011; 46: 283.
52. Boyle MP, Bell S, Konstan MW, et al. VX-809, an investigational CFTR corrector, in combination with VX-770, an investigational CFTR potentiator, in subjects with CF and homozygous for the F508del-CFTR mutation. Pediatric Pulmonology 2011; 46: 212-428.
53. Konstan MW, Davis PB, Wagener JS, et al. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum Gene Ther 2004; 15: 1255-1269.
54. Noone PG, Hohneker KW, Zhou Z, et al. Safety and biological efficacy of a lipid-CFTR complex for gene transfer in the nasal epithelium of adult patients with cystic fibrosis. Mol Ther 2000; 1: 105-114.
55. Alton EW, Stern M, Farley R, et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet 1999; 353: 947-954.
56. Zabner J, Cheng SH, Meeker D, et al. Comparison of DNA-lipid complexes and DNA alone for gene transfer to cystic fibrosis airway epithelia in vivo. J Clin Invest 1997; 100: 1529-1537.
57. Porteous DJ, Dorin JR, McLachlan G, et al. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 1997; 4: 210-218.
58. Zabner J, Ramsey BW, Meeker DP, et al. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J Clin Invest 1996; 97: 1504-1511.
59. Gill DR, Southern KW, Mofford KA, et al. A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 1997; 4: 199-209.
60. Caplen NJ, Alton EW, Middleton PG, et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med 1995; 1: 39-46.
61. Hay JG, McElvaney NG, Herena J, et al. Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector. Hum Gene Ther 1995; 6: 1487-1496.
62. McCarty NA, Standaert TA, Teresi M, et al. A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis. Pediatr Pulmonol 2002; 33: 90-98.
63. Zeitlin PL, Boyle MP, Guggino WB, et al. A phase I trial of intranasal Moli1901 for cystic fibrosis. Chest 2004; 125: 143-149.
64. Rubenstein RC, Zeitlin PL. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 1998; 157: 484-490.
65. Rodgers HC, Knox AJ. The effect of topical benzamil and amiloride on nasal potential difference in cystic fibrosis. Eur Respir J 1999; 14: 693-696.
66. Hofmann T, Senier I, Bittner P, et al. Aerosolized amiloride: dose effect on nasal bioelectric properties, pharmacokinetics, and effect on sputum expectoration in patients with cystic fibrosis. J Aerosol Med 1997; 10: 147-158.
67. Hofmann T, Stutts MJ, Ziersch A, et al. Effects of topically delivered benzamil and amiloride on nasal potential difference in cystic fibrosis. Am J Respir Crit Care Med 1998; 157: 1844-1849.
68. Pyle LC, Fulton JC, Sloane PA, et al. Activation of the cystic fibrosis transmembrane conductance regulator by the flavonoid quercetin: potential use as a biomarker of DeltaF508 cystic fibrosis transmembrane conductance regulator rescue. Am J Respir Cell Mol Biol 2010; 43: 607-616.
69. Illek B, Fischer H. Flavonoids stimulate Cl conductance of human airway epithelium in vitro and in vivo. Am J Physiol 1998; 275: L902-L910.
70. Middleton PG, Pollard KA, Wheatley JR. Hypertonic saline alters ion transport across the human airway epithelium. Eur Respir J 2001; 17: 195-199.
71. Graham SM, Scott SN, Launspach J, et al. The effects of fluticasone propionate on nasal epithelial potential difference. Am J Rhinol 2002; 16: 145-149.
72. Smith SN, Middleton PG, Chadwick S, et al. The in vivo effects of milrinone on the airways of cystic fibrosis mice and human subjects. Am J Respir Cell Mol Biol 1999; 20: 129-134.
73. Boyle MP, Diener-West M, Milgram L, et al. A multicenter study of the effect of solution temperature on nasal potential difference measurements. Chest 2003; 124: 482-489.
74. Solomon GM, Konstan MW, Wilschanski M, et al. An international randomized multicenter comparison of nasal potential difference techniques. Chest 2010; 138: 919-928.
75. Alsuwaidan S, Li Wan Po A, Morrison G, et al. Effect of exercise on the nasal transmucosal potential difference in patients with cystic fibrosis and normal subjects. Thorax 1994; 49: 1249-1250.
76. Hebestreit A, Kersting U, Basler B, et al. Exercise inhibits epithelial sodium channels in patients with cystic fibrosis. Am J Respir Crit Care Med 2001; 164: 443-446.
77. Sermet-Gaudelus I, Girodon E, Roussel D, et al. Measurement of nasal potential difference in young children with an equivocal sweat test following newborn screening for cystic fibrosis. Thorax 2010; 65: 539-544.
78. Sermet-Gaudelus I, Girodon E, Sands D, et al. Clinical phenotype and genotype of children with borderline sweat test and abnormal nasal epithelial chloride transport. Am J Respir Crit Care Med 2010; 182: 929-936.
79. Wilschanski M, Famini H, Strauss-Liviatan N, et al. Nasal potential difference measurements in patients with atypical cystic fibrosis. Eur Respir J 2001; 17: 1208-1215.
80. Berschneider HM, Knowles MR, Azizkhan RG, et al. Altered intestinal chloride transport in cystic fibrosis. FASEB J 1988; 2: 2625-2629.
81. Hardcastle J, Hardcastle PT, Taylor CJ, et al. Failure of cholinergic stimulation to induce a secretory response from the rectal mucosa in cystic fibrosis. Gut 1991; 32: 1035-1039.
82. - channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis. Gastroenterology 2004; 127: 1085-1095.
83. + conductance in human colon is defective in cystic fibrosis. Am J Physiol 1999; 277: G709-G716.
84. + secretion in rectal biopsies from cystic fibrosis patients. Am J Physiol Gastrointest Liver Physiol 2000; 278: G617-G624.
85. Taylor CJ, Baxter PS, Hardcastle J, et al. Failure to induce secretion in jejunal biopsies from children with cystic fibrosis. Gut 1988; 29: 957-962.
86. Taylor CJ, Hughes H, Hardcastle PT, et al. Genotype and secretory response in cystic fibrosis. Lancet 1992; 339: 67-68.
87. LeGrys VA, Yankaskas JR, Quittell LM, et al. Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines. J Pediatr 2007; 151: 85-89.
88. Legrys VA, McColley SA, Li Z, et al. The need for quality improvement in sweat testing infants after newborn screening for cystic fibrosis. J Pediatr 2010; 157: 1035-1037.
89. Southern KW, Noone PG, Bosworth DG, et al. A modified technique for measurement of nasal transepithelial potential difference in infants. J Pediatr 2001; 139: 353-358.
90. Clancy JP. Diagnosing cystic fibrosis in patients with non-diagnostic results: the case for intestinal current measurements. Thorax 2010; 65: 575-576.
91. Davies JC, Davies M, McShane D, et al. Potential difference measurements in the lower airway of children with and without cystic fibrosis. Am J Respir Crit Care Med 2005; 171: 1015-1019.
92. Wilschanski M, Miller LL, Shoseyov D, et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 2011; 38: 59-69.
93. Derichs N, Knoll J, Hyde R, et al. Preclinical evaluation of CFTR modulators in ex vivo human rectal tissue. Pediatric Pulmonology 2009; 44: 231.
94. Derichs N, Tran D, Namkung W, et al. Correction o ΔF508-CFTR in human airway epithelia and ex vivo rectal biopsies by s-cis-locked bithiazole corrector-29. J Cystic Fibros 2011; 10: Suppl. 1, S17.
95. Garcia MA, Yang N, Quinton PM. Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion. J Clin Invest 2009; 119: 2613-2622.
96. Amaral MD, Kunzelmann K. Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis. Trends Pharmacol Sci 2007; 28: 334-341.
97. Wang F, Zeltwanger S, Hu S, et al. Deletion of phenylalanine 508 causes attenuated phosphorylation-dependent activation of CFTR chloride channels. J Physiol 2000; 524: 637-648.
98. US Food and Drug Administration. Food and Drug Administration Modernization Act. 1997.
99. Committee for Medicinal Products for Human Use. Guideline on Clinical Trials in Small Populations. London, European Medicines Agency, 2006.
100. Vertex Pharmaceuticals Inc. Interim Phase 2 Data Showed a Combination of VX-770 and VX-809 Improved Function of the Defective Protein that Causes Cystic Fibrosis in People With the Most Common Form of the Disease. http://investors.vrtx.com/releasedetail.cfm?ReleaseID5583683 Date last updated: June 9, 2011. Date last accessed: November 6, 2012.
101. Dolmage TE, Hill K, Evans RA, et al. Has my patient responded? Interpreting clinical measurements such as the 6-minute-walk test. Am J Respir Crit Care Med 2011; 184: 642-646.